| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 16 | 2006 | 782 | 1.150 |
Why?
|
| Mercaptopurine | 6 | 2006 | 71 | 0.590 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2006 | 1251 | 0.490 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2001 | 128 | 0.480 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2006 | 184 | 0.430 |
Why?
|
| Brain Neoplasms | 7 | 2008 | 1215 | 0.400 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2020 | 136 | 0.400 |
Why?
|
| Methotrexate | 8 | 2005 | 337 | 0.390 |
Why?
|
| Medulloblastoma | 4 | 2008 | 325 | 0.330 |
Why?
|
| Neutropenia | 3 | 2000 | 197 | 0.310 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2008 | 42 | 0.300 |
Why?
|
| Folic Acid Deficiency | 1 | 2008 | 53 | 0.300 |
Why?
|
| Anemia, Sickle Cell | 3 | 2005 | 330 | 0.300 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 55 | 0.290 |
Why?
|
| Child, Preschool | 38 | 2020 | 13882 | 0.290 |
Why?
|
| Iron | 3 | 2020 | 270 | 0.270 |
Why?
|
| Meningeal Neoplasms | 2 | 2008 | 185 | 0.270 |
Why?
|
| Radiation Injuries | 1 | 2008 | 142 | 0.270 |
Why?
|
| Carboplatin | 2 | 2000 | 76 | 0.270 |
Why?
|
| Meningioma | 1 | 2008 | 120 | 0.270 |
Why?
|
| Bone Marrow | 4 | 1998 | 323 | 0.260 |
Why?
|
| Leukemia, Lymphoid | 7 | 1988 | 109 | 0.250 |
Why?
|
| Hodgkin Disease | 3 | 1998 | 294 | 0.240 |
Why?
|
| Salvage Therapy | 1 | 2006 | 192 | 0.230 |
Why?
|
| Child | 41 | 2015 | 24170 | 0.210 |
Why?
|
| Infant | 24 | 2020 | 12381 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 1996 | 72 | 0.200 |
Why?
|
| Pulmonary Artery | 1 | 2005 | 442 | 0.190 |
Why?
|
| Central Nervous System Diseases | 2 | 1998 | 107 | 0.190 |
Why?
|
| Infusions, Intravenous | 5 | 2006 | 554 | 0.190 |
Why?
|
| Myelodysplastic Syndromes | 2 | 1996 | 139 | 0.190 |
Why?
|
| Administration, Oral | 6 | 2020 | 683 | 0.180 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2001 | 27 | 0.180 |
Why?
|
| Male | 44 | 2020 | 61314 | 0.180 |
Why?
|
| Hypertension, Pulmonary | 1 | 2005 | 438 | 0.180 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2001 | 127 | 0.180 |
Why?
|
| Humans | 67 | 2020 | 124700 | 0.180 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2000 | 19 | 0.170 |
Why?
|
| Antineoplastic Agents | 5 | 2000 | 1695 | 0.170 |
Why?
|
| Splenectomy | 2 | 2012 | 64 | 0.170 |
Why?
|
| Multi-Institutional Systems | 1 | 2000 | 12 | 0.170 |
Why?
|
| Leukopenia | 1 | 2000 | 44 | 0.170 |
Why?
|
| Nonprescription Drugs | 1 | 2000 | 50 | 0.160 |
Why?
|
| Female | 41 | 2020 | 66570 | 0.160 |
Why?
|
| Zinc | 1 | 2000 | 133 | 0.160 |
Why?
|
| Adolescent | 27 | 2012 | 19216 | 0.160 |
Why?
|
| Critical Pathways | 1 | 2000 | 76 | 0.160 |
Why?
|
| Cytomegalovirus Infections | 1 | 2001 | 218 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2001 | 249 | 0.150 |
Why?
|
| Program Development | 1 | 2000 | 185 | 0.150 |
Why?
|
| Thrombosis | 2 | 2015 | 526 | 0.150 |
Why?
|
| Ventricular Function, Left | 1 | 2001 | 508 | 0.150 |
Why?
|
| Glioma | 2 | 2000 | 491 | 0.140 |
Why?
|
| Gene Amplification | 1 | 1998 | 230 | 0.140 |
Why?
|
| Burkitt Lymphoma | 2 | 1998 | 144 | 0.140 |
Why?
|
| Heart | 1 | 2001 | 729 | 0.130 |
Why?
|
| Ganglioglioma | 1 | 1996 | 22 | 0.130 |
Why?
|
| Isochromosomes | 1 | 1996 | 18 | 0.130 |
Why?
|
| Anemia | 1 | 2000 | 339 | 0.130 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 1 | 2015 | 9 | 0.130 |
Why?
|
| Remission Induction | 7 | 1998 | 300 | 0.130 |
Why?
|
| Combined Modality Therapy | 7 | 2012 | 1236 | 0.120 |
Why?
|
| Chromosome Aberrations | 2 | 1998 | 612 | 0.120 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2012 | 49 | 0.120 |
Why?
|
| Antithrombin III | 1 | 2015 | 25 | 0.120 |
Why?
|
| Bone Marrow Transplantation | 2 | 1996 | 573 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2006 | 1143 | 0.120 |
Why?
|
| Anemia, Hemolytic, Congenital Nonspherocytic | 1 | 1995 | 1 | 0.120 |
Why?
|
| Pyruvate Kinase | 1 | 1995 | 8 | 0.120 |
Why?
|
| Hospitals, Pediatric | 1 | 2000 | 749 | 0.120 |
Why?
|
| Mediastinal Cyst | 1 | 1994 | 10 | 0.120 |
Why?
|
| Mediastinal Diseases | 1 | 1994 | 15 | 0.120 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 1995 | 73 | 0.120 |
Why?
|
| Disease-Free Survival | 4 | 2015 | 897 | 0.110 |
Why?
|
| Bronchiolitis | 1 | 1995 | 120 | 0.110 |
Why?
|
| Isoenzymes | 1 | 1995 | 228 | 0.110 |
Why?
|
| Parvovirus | 1 | 1993 | 8 | 0.110 |
Why?
|
| Heparin | 1 | 2015 | 225 | 0.110 |
Why?
|
| Lymphocytes | 1 | 1995 | 410 | 0.110 |
Why?
|
| Parvoviridae Infections | 1 | 1993 | 36 | 0.110 |
Why?
|
| Panniculitis | 1 | 1993 | 19 | 0.110 |
Why?
|
| Abscess | 1 | 1994 | 135 | 0.110 |
Why?
|
| Purpura | 1 | 1993 | 24 | 0.110 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 1995 | 204 | 0.100 |
Why?
|
| Hematoma | 1 | 1993 | 93 | 0.100 |
Why?
|
| Diagnosis, Differential | 4 | 2008 | 1872 | 0.100 |
Why?
|
| Haemophilus Vaccines | 1 | 1992 | 30 | 0.100 |
Why?
|
| Organoplatinum Compounds | 1 | 1992 | 28 | 0.100 |
Why?
|
| Tetanus Toxoid | 1 | 1992 | 45 | 0.100 |
Why?
|
| Acute Disease | 5 | 2015 | 1107 | 0.100 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 1995 | 342 | 0.100 |
Why?
|
| Bacterial Vaccines | 1 | 1992 | 97 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2009 | 2092 | 0.090 |
Why?
|
| Haemophilus Infections | 1 | 1992 | 90 | 0.090 |
Why?
|
| Haemophilus influenzae | 1 | 1992 | 129 | 0.090 |
Why?
|
| Mutation | 2 | 2015 | 5845 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2000 | 1357 | 0.090 |
Why?
|
| Splenic Infarction | 1 | 1991 | 4 | 0.090 |
Why?
|
| Protein C Deficiency | 1 | 1991 | 12 | 0.090 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 1991 | 30 | 0.090 |
Why?
|
| Survival Rate | 5 | 2005 | 2055 | 0.090 |
Why?
|
| Drug Administration Schedule | 4 | 2000 | 715 | 0.090 |
Why?
|
| Anticoagulants | 1 | 2015 | 592 | 0.090 |
Why?
|
| Thalassemia | 1 | 2010 | 11 | 0.080 |
Why?
|
| Antibodies, Bacterial | 1 | 1992 | 388 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2012 | 369 | 0.080 |
Why?
|
| Chlorambucil | 1 | 1989 | 6 | 0.080 |
Why?
|
| Injections, Spinal | 4 | 1998 | 124 | 0.080 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1988 | 7 | 0.080 |
Why?
|
| gamma-Globulins | 1 | 1988 | 6 | 0.080 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 1990 | 538 | 0.080 |
Why?
|
| Vitamin B 12 | 1 | 2008 | 59 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1989 | 94 | 0.080 |
Why?
|
| Survival Analysis | 4 | 2000 | 1504 | 0.080 |
Why?
|
| von Willebrand Diseases | 1 | 2009 | 51 | 0.070 |
Why?
|
| Adult | 10 | 2020 | 29555 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 221 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 1685 | 0.070 |
Why?
|
| Antidotes | 2 | 1998 | 13 | 0.070 |
Why?
|
| Bone Neoplasms | 2 | 1986 | 419 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2010 | 3561 | 0.070 |
Why?
|
| Blood Cell Count | 2 | 2000 | 70 | 0.070 |
Why?
|
| Leucovorin | 2 | 1998 | 49 | 0.070 |
Why?
|
| Agranulocytosis | 1 | 1987 | 13 | 0.070 |
Why?
|
| Glycogen Storage Disease Type I | 1 | 1987 | 11 | 0.070 |
Why?
|
| Wilms Tumor | 1 | 2009 | 112 | 0.070 |
Why?
|
| Lithium | 1 | 1987 | 66 | 0.070 |
Why?
|
| Skin Diseases | 1 | 1989 | 129 | 0.070 |
Why?
|
| Nutrition Surveys | 1 | 2008 | 293 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2012 | 493 | 0.070 |
Why?
|
| Sex Factors | 4 | 2000 | 1287 | 0.070 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1989 | 205 | 0.070 |
Why?
|
| Karyotyping | 2 | 1998 | 323 | 0.070 |
Why?
|
| Staphylococcal Infections | 2 | 2006 | 558 | 0.060 |
Why?
|
| Folic Acid | 1 | 2008 | 294 | 0.060 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 1989 | 221 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 1989 | 646 | 0.060 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2005 | 112 | 0.060 |
Why?
|
| Polyglutamic Acid | 1 | 2005 | 5 | 0.060 |
Why?
|
| Follow-Up Studies | 4 | 2005 | 5154 | 0.060 |
Why?
|
| Prognosis | 5 | 2015 | 4620 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 3154 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 2043 | 0.060 |
Why?
|
| Vincristine | 4 | 1995 | 191 | 0.060 |
Why?
|
| Treatment Outcome | 6 | 2005 | 12363 | 0.060 |
Why?
|
| Hearing Loss, High-Frequency | 1 | 1983 | 1 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 183 | 0.060 |
Why?
|
| Myelin Basic Protein | 1 | 1984 | 68 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2005 | 4799 | 0.050 |
Why?
|
| Osteomyelitis | 1 | 2006 | 205 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2015 | 4534 | 0.050 |
Why?
|
| Algorithms | 1 | 2010 | 1625 | 0.050 |
Why?
|
| Cerebellar Neoplasms | 1 | 1986 | 275 | 0.050 |
Why?
|
| Prednisone | 5 | 1995 | 271 | 0.050 |
Why?
|
| Staphylococcus aureus | 1 | 2006 | 460 | 0.050 |
Why?
|
| Hearing Loss | 1 | 1983 | 135 | 0.050 |
Why?
|
| Leukocyte Count | 2 | 2000 | 251 | 0.050 |
Why?
|
| Cisplatin | 1 | 1983 | 249 | 0.050 |
Why?
|
| Disease Progression | 2 | 2015 | 2058 | 0.050 |
Why?
|
| Prevalence | 1 | 2008 | 2446 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 1981 | 688 | 0.050 |
Why?
|
| Coombs Test | 1 | 2001 | 6 | 0.050 |
Why?
|
| Immune Sera | 1 | 2001 | 95 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 1113 | 0.050 |
Why?
|
| Urine | 1 | 2001 | 90 | 0.050 |
Why?
|
| Pilot Projects | 2 | 1996 | 1396 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2001 | 91 | 0.050 |
Why?
|
| Nasopharynx | 1 | 2001 | 79 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2001 | 120 | 0.040 |
Why?
|
| Monocytes | 1 | 1983 | 353 | 0.040 |
Why?
|
| Self Medication | 1 | 2000 | 23 | 0.040 |
Why?
|
| Acne Vulgaris | 1 | 2000 | 21 | 0.040 |
Why?
|
| Oncology Nursing | 1 | 2000 | 9 | 0.040 |
Why?
|
| Risk Factors | 2 | 2008 | 10249 | 0.040 |
Why?
|
| Ploidies | 1 | 2000 | 37 | 0.040 |
Why?
|
| Copper | 1 | 2000 | 64 | 0.040 |
Why?
|
| Pediatric Nursing | 1 | 2000 | 21 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2001 | 269 | 0.040 |
Why?
|
| Base Sequence | 2 | 1995 | 3101 | 0.040 |
Why?
|
| Electroencephalography | 2 | 1981 | 864 | 0.040 |
Why?
|
| Aspergillosis | 1 | 1979 | 43 | 0.040 |
Why?
|
| Leukemia | 2 | 1990 | 371 | 0.040 |
Why?
|
| Treatment Failure | 2 | 1998 | 335 | 0.040 |
Why?
|
| Chronic Disease | 3 | 2012 | 1191 | 0.040 |
Why?
|
| Recurrence | 2 | 1993 | 1415 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 1995 | 3891 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2000 | 217 | 0.040 |
Why?
|
| Brain | 4 | 2001 | 2997 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1979 | 71 | 0.040 |
Why?
|
| Young Adult | 2 | 2010 | 9022 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2001 | 775 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 1982 | 417 | 0.040 |
Why?
|
| B-Lymphocytes | 2 | 2005 | 533 | 0.040 |
Why?
|
| Platelet Count | 3 | 2012 | 136 | 0.040 |
Why?
|
| Injections, Intramuscular | 2 | 1995 | 194 | 0.040 |
Why?
|
| Herpesviridae Infections | 2 | 1989 | 142 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2005 | 534 | 0.030 |
Why?
|
| Neoplasms | 1 | 1992 | 2780 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 1979 | 318 | 0.030 |
Why?
|
| Patient Selection | 1 | 2000 | 697 | 0.030 |
Why?
|
| Subarachnoid Space | 1 | 1996 | 24 | 0.030 |
Why?
|
| Monosomy | 1 | 1996 | 24 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1998 | 762 | 0.030 |
Why?
|
| Echocardiography | 1 | 2001 | 1053 | 0.030 |
Why?
|
| Melphalan | 1 | 1996 | 49 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 1979 | 253 | 0.030 |
Why?
|
| Germinoma | 1 | 1996 | 30 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1996 | 144 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 69 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2000 | 541 | 0.030 |
Why?
|
| Leukemia, Myeloid | 1 | 2015 | 85 | 0.030 |
Why?
|
| Asparaginase | 1 | 1995 | 41 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 1 | 2015 | 47 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 1996 | 298 | 0.030 |
Why?
|
| DNA, Satellite | 1 | 1995 | 18 | 0.030 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1995 | 70 | 0.030 |
Why?
|
| Antithrombins | 1 | 2015 | 56 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1996 | 361 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2001 | 1151 | 0.030 |
Why?
|
| Factor Xa Inhibitors | 1 | 2015 | 64 | 0.030 |
Why?
|
| Ependymoma | 1 | 1996 | 125 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 604 | 0.030 |
Why?
|
| United States | 2 | 2000 | 10866 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2012 | 16262 | 0.030 |
Why?
|
| Staphylococcus | 1 | 1994 | 69 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 1998 | 1277 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 1996 | 312 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1995 | 369 | 0.030 |
Why?
|
| Age Factors | 2 | 2000 | 2807 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 1996 | 417 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 1996 | 1080 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2020 | 6132 | 0.030 |
Why?
|
| Haplotypes | 1 | 1995 | 522 | 0.030 |
Why?
|
| Catheterization, Central Venous | 1 | 1994 | 131 | 0.030 |
Why?
|
| Parents | 1 | 2020 | 1022 | 0.030 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1992 | 7 | 0.030 |
Why?
|
| Pons | 1 | 1993 | 32 | 0.030 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2012 | 8 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2012 | 312 | 0.030 |
Why?
|
| Demyelinating Diseases | 1 | 1993 | 64 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 1995 | 794 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 1995 | 197 | 0.020 |
Why?
|
| Pancytopenia | 1 | 1992 | 41 | 0.020 |
Why?
|
| Bites and Stings | 1 | 2012 | 29 | 0.020 |
Why?
|
| Pentosephosphates | 1 | 1992 | 8 | 0.020 |
Why?
|
| Isoantibodies | 1 | 2012 | 72 | 0.020 |
Why?
|
| Drug Costs | 1 | 2012 | 60 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1992 | 107 | 0.020 |
Why?
|
| Wound Infection | 1 | 2012 | 53 | 0.020 |
Why?
|
| DNA, Viral | 1 | 1993 | 480 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 1993 | 175 | 0.020 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1992 | 68 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 1993 | 229 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2012 | 144 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 1995 | 814 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1695 | 0.020 |
Why?
|
| Dogs | 1 | 2012 | 774 | 0.020 |
Why?
|
| Pedigree | 1 | 1995 | 1604 | 0.020 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 1990 | 2 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 1995 | 1330 | 0.020 |
Why?
|
| Pyoderma | 1 | 1990 | 2 | 0.020 |
Why?
|
| Deficiency Diseases | 1 | 1991 | 11 | 0.020 |
Why?
|
| Hemiplegia | 1 | 1991 | 45 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2012 | 178 | 0.020 |
Why?
|
| Ischemic Attack, Transient | 1 | 1991 | 57 | 0.020 |
Why?
|
| Neutrophils | 1 | 1993 | 382 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 1992 | 152 | 0.020 |
Why?
|
| Thrombocythemia, Essential | 1 | 1991 | 29 | 0.020 |
Why?
|
| Mesenteric Arteries | 1 | 1991 | 57 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1993 | 434 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 949 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1992 | 121 | 0.020 |
Why?
|
| Cecal Diseases | 1 | 1990 | 6 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 882 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2012 | 292 | 0.020 |
Why?
|
| Bacteremia | 1 | 1994 | 406 | 0.020 |
Why?
|
| Quinazolines | 1 | 1991 | 174 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 1578 | 0.020 |
Why?
|
| Sarcoma | 1 | 1992 | 181 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1990 | 96 | 0.020 |
Why?
|
| Middle Aged | 1 | 2008 | 26884 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 2 | 1989 | 675 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2010 | 163 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1991 | 269 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 650 | 0.020 |
Why?
|
| Necrosis | 2 | 1990 | 207 | 0.020 |
Why?
|
| Anemia, Aplastic | 1 | 1988 | 58 | 0.020 |
Why?
|
| Infant, Newborn | 4 | 2015 | 8162 | 0.020 |
Why?
|
| Lithium Carbonate | 1 | 1987 | 20 | 0.020 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 1987 | 10 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 1993 | 3055 | 0.020 |
Why?
|
| Thigh | 1 | 1987 | 51 | 0.020 |
Why?
|
| Ultrasonography | 2 | 1982 | 938 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1329 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 1988 | 505 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 118 | 0.020 |
Why?
|
| Bone Marrow Diseases | 1 | 1986 | 41 | 0.020 |
Why?
|
| Brain Diseases | 1 | 1988 | 296 | 0.010 |
Why?
|
| Bacterial Infections | 2 | 1990 | 308 | 0.010 |
Why?
|
| Community-Acquired Infections | 1 | 2006 | 239 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 177 | 0.010 |
Why?
|
| Mechlorethamine | 2 | 1993 | 8 | 0.010 |
Why?
|
| Procarbazine | 2 | 1993 | 12 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2885 | 0.010 |
Why?
|
| Seizures | 1 | 1988 | 870 | 0.010 |
Why?
|
| Phagocytosis | 1 | 1983 | 171 | 0.010 |
Why?
|
| Urography | 1 | 1981 | 31 | 0.010 |
Why?
|
| Levamisole | 1 | 1981 | 4 | 0.010 |
Why?
|
| Biomarkers | 1 | 2010 | 3083 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 1981 | 57 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2012 | 3067 | 0.010 |
Why?
|
| BCG Vaccine | 1 | 1981 | 101 | 0.010 |
Why?
|
| Air Movements | 1 | 1979 | 1 | 0.010 |
Why?
|
| Maintenance and Engineering, Hospital | 1 | 1979 | 1 | 0.010 |
Why?
|
| Air Conditioning | 1 | 1979 | 2 | 0.010 |
Why?
|
| Air Microbiology | 1 | 1979 | 11 | 0.010 |
Why?
|
| Testis | 1 | 1981 | 409 | 0.010 |
Why?
|
| Technetium | 1 | 1979 | 12 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1983 | 505 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1979 | 149 | 0.010 |
Why?
|
| Biopsy | 1 | 1981 | 1234 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1998 | 302 | 0.010 |
Why?
|
| Texas | 2 | 1992 | 3561 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1981 | 618 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1981 | 375 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1981 | 1090 | 0.010 |
Why?
|
| Cross Infection | 1 | 1979 | 319 | 0.010 |
Why?
|
| Kidney | 1 | 1981 | 1367 | 0.010 |
Why?
|
| Coagulase | 1 | 1994 | 23 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1994 | 50 | 0.010 |
Why?
|
| Liver | 1 | 1981 | 1742 | 0.010 |
Why?
|
| Teniposide | 1 | 1993 | 2 | 0.010 |
Why?
|
| Daunorubicin | 1 | 1993 | 27 | 0.010 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 1993 | 30 | 0.010 |
Why?
|
| Cytarabine | 1 | 1993 | 98 | 0.010 |
Why?
|
| Vinblastine | 1 | 1993 | 53 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1993 | 248 | 0.010 |
Why?
|
| Dacarbazine | 1 | 1993 | 95 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1993 | 218 | 0.010 |
Why?
|
| Bleomycin | 1 | 1993 | 153 | 0.010 |
Why?
|
| Cranial Irradiation | 1 | 1992 | 67 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1993 | 231 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1993 | 290 | 0.010 |
Why?
|
| Dysarthria | 1 | 1991 | 22 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 34234 | 0.010 |
Why?
|
| Gangrene | 1 | 1990 | 26 | 0.010 |
Why?
|
| Mumps | 1 | 1970 | 11 | 0.010 |
Why?
|
| Environment, Controlled | 1 | 1990 | 8 | 0.010 |
Why?
|
| Patient Isolation | 1 | 1990 | 12 | 0.010 |
Why?
|
| Filtration | 1 | 1990 | 23 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 1990 | 64 | 0.010 |
Why?
|
| Autopsy | 1 | 1990 | 111 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1993 | 1399 | 0.010 |
Why?
|
| Aspirin | 1 | 1991 | 221 | 0.000 |
Why?
|
| Immune Tolerance | 1 | 1990 | 144 | 0.000 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1990 | 183 | 0.000 |
Why?
|
| Population Surveillance | 1 | 1970 | 386 | 0.000 |
Why?
|
| Sciatic Nerve | 1 | 1987 | 56 | 0.000 |
Why?
|
| Frontal Lobe | 1 | 1988 | 116 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1991 | 1159 | 0.000 |
Why?
|
| Graft vs Host Disease | 1 | 1990 | 540 | 0.000 |
Why?
|
| Neoplasm Invasiveness | 1 | 1987 | 620 | 0.000 |
Why?
|
| Inflammation | 1 | 1990 | 1440 | 0.000 |
Why?
|
| Incidence | 1 | 1990 | 3115 | 0.000 |
Why?
|
| Time Factors | 1 | 1988 | 6323 | 0.000 |
Why?
|
| Florida | 1 | 1970 | 78 | 0.000 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 1970 | 114 | 0.000 |
Why?
|
| Serologic Tests | 1 | 1970 | 117 | 0.000 |
Why?
|